Short Interest in Petros Pharmaceuticals, Inc. (NASDAQ:PTPI) Rises By 139.6%

Petros Pharmaceuticals, Inc. (NASDAQ:PTPI) was the recipient of a significant increase in short interest in the month of December. As of December 31st, there was short interest totalling 646,200 shares, an increase of 139.6% from the December 15th total of 269,700 shares. Based on an average daily trading volume, of 1,910,000 shares, the short-interest ratio is currently 0.3 days. Approximately 7.1% of the company’s shares are sold short.

Petros Pharmaceuticals Trading Down 10.0 %

PTPI stock traded down $0.03 on Tuesday, reaching $0.31. The company’s stock had a trading volume of 804,990 shares, compared to its average volume of 2,784,349. The firm has a market cap of $3.11 million, a PE ratio of -0.07 and a beta of 1.85. The business has a fifty day simple moving average of $0.32 and a two-hundred day simple moving average of $0.35. Petros Pharmaceuticals has a 12-month low of $0.22 and a 12-month high of $2.27. The company has a debt-to-equity ratio of 1.58, a quick ratio of 0.74 and a current ratio of 0.85.

Petros Pharmaceuticals Company Profile

Petros Pharmaceuticals, Inc, a pharmaceutical company, focuses on men's health therapeutics in the United States and internationally. It operates through two segments, Prescription Medications and Medical Devices. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED).